Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3504585 | 1.00 | BCHE (0.46) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL20961003 | 0.90 | BCHE (0.47) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL22517725 | 0.84 | BCHE (0.47) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL28262599 | 0.81 | BCHE (0.55) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL22892187 | 0.79 | BCHE (0.49) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL14461205 | 0.78 | CHRNA7 (0.54) | BCHECHRNA7MEN1KMT2AHTR3E | |
| SCHEMBL22101385 | 0.78 | CHRNA7 (0.54) | BCHECHRNA7MEN1KMT2AHTR3E | |
| SCHEMBL27471274 | 0.78 | SLC18A3 (0.55) | BCHECHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL21886707 | 0.78 | CHRNA7 (0.54) | BCHECHRNA7MEN1KMT2AHTR3E | |
| SCHEMBL31083157 | 0.78 | BCHE (0.42) | BCHECHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028600-A1 | TRANSAMINASE POLYPEPTIDES | CODEXIS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12448611-B2 | Transaminase polypeptides | CODEXIS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240150732-A1 | TRANSAMINASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2024-05-09 | — | — | US | disclosed |
| US-11939602-B2 | Transaminase polypeptides | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2024-03-26 | — | — | US | disclosed |
| US-20230120624-A1 | TRANSAMINASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2023-04-20 | — | — | US | disclosed |
| US-11542485-B2 | Transaminase polypeptides | CODEXIS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542485-B2 | Transaminase polypeptides | CODEXIS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210230564-A1 | TRANSAMINASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-07-29 | — | — | US | disclosed |
| US-20210230564-A1 | TRANSAMINASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-07-29 | — | — | US | disclosed |
| US-10995323-B2 | Transaminase polypeptides | CODEXIS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20130266994-A1 | TRANSAMINASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2013-10-10 | — | — | US | disclosed |
| US-20130266994-A1 | TRANSAMINASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2013-10-10 | — | — | US | disclosed |
| US-20130266994-A1 | TRANSAMINASE POLYPEPTIDES | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2013-10-10 | — | — | US | disclosed |
| US-8470564-B2 | Transaminase polypeptides | CODEXIS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470564-B2 | Transaminase polypeptides | CODEXIS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8470564-B2 | Transaminase polypeptides | CODEXIS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20100209981-A1 | TRANSAMINASE POLYPEPTIDES | CODEXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100209981-A1 | TRANSAMINASE POLYPEPTIDES | CODEXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100209981-A1 | TRANSAMINASE POLYPEPTIDES | CODEXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| WO-2010081053-A2 | TRANSAMINASE POLYPEPTIDES | CODEXIS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028600-A1 | TRANSAMINASE POLYPEPTIDES | GOT1, OAT, PEPD | BCHE 324/4885CHRM2 2146/4885CHRM4 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.